Schizophrenia affects an estimated 3.2 million adults in the United States, which represents about 1.2% of the adult population. A core and disabling feature of schizophrenia is cognitive impairment, affecting abilities such as memory, attention, processing speed, and executive function. This condition, known as Cognitive Impairment Associated with Schizophrenia (CIAS), impacts the patients' ability to work, maintain social relationships, and live independently. Currently, there are no approved treatments for CIAS.
The stock we are bringing to your attention today is that of Alto Neuroscience Inc. (ANRO), a clinical-stage biopharmaceutical company, developing a drug for cognitive impairment associated with schizophrenia.
For comments and feedback: editorial@rttnews.com